1. Home
  2. AXTA vs BLTE Comparison

AXTA vs BLTE Comparison

Compare AXTA & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Axalta Coating Systems Ltd.

AXTA

Axalta Coating Systems Ltd.

HOLD

Current Price

$34.39

Market Cap

6.9B

ML Signal

HOLD

Logo Belite Bio Inc

BLTE

Belite Bio Inc

HOLD

Current Price

$143.91

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AXTA
BLTE
Founded
1910
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Paints/Coatings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9B
6.0B
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
AXTA
BLTE
Price
$34.39
$143.91
Analyst Decision
Buy
Strong Buy
Analyst Count
18
9
Target Price
$39.00
★ $228.89
AVG Volume (30 Days)
★ 1.6M
128.3K
Earning Date
10-29-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.42
N/A
Revenue
★ $5,117,000,000.00
N/A
Revenue This Year
$2.37
N/A
Revenue Next Year
$2.98
N/A
P/E Ratio
$81.64
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$24.94
$91.40
52 Week High
$38.61
$200.00

Technical Indicators

Market Signals
Indicator
AXTA
BLTE
Relative Strength Index (RSI) 55.32 35.98
Support Level $33.24 $132.50
Resistance Level $35.48 $161.08
Average True Range (ATR) 0.71 5.99
MACD 0.23 -0.62
Stochastic Oscillator 67.82 6.50

Price Performance

Historical Comparison
AXTA
BLTE

About AXTA Axalta Coating Systems Ltd.

Axalta Coating Systems Ltd is a manufacturer, marketer, and distributor of high-performance coatings systems. It operates in two segments: Performance Coatings and Mobility Coatings. The Performance Coatings segment provides liquid and powder coatings solutions to a fragmented and local customer base. Its end markets include refinish and industrial, and the Mobility Coatings segment relates to the provision of coating technologies to original equipment manufacturers of light and commercial vehicles. The majority of its revenue is generated from the Mobility Coatings segment. Geographically, the company generates maximum revenue from the Europe, Middle East and Africa (EMEA) region, followed by North America, Asia Pacific, and Latin America.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: